We leverage our proprietary kinase switch control inhibitor platform to develop of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers.

 Pre-ClinicalPhase 1Phase 1b/2Phase 3Regulatory SubmissionCommercial Rights
Ripretinib: Broad Spectrum Inhibitor of KIT & PDGFRα
GIST ≥4th Line (INVICTUS Study)
 
    Deciphera Logo*
      
GIST 2nd Line (INTRIGUE Study)
 
    
      
Systemic Mastocytosis and Other Solid Tumors 
 

 

    
DCC-3014: Selective Inhibitor of CSF1R
Tenosynovial Giant Cell Tumors
 
    Deciphera Logo
      
Other Solid Tumors 
 

 

    
Rebastinib: Selective Inhibitor of TIE2
Solid Tumors in Combination with Paclitaxel
(includes breast, ovarian & endometrial cancers)
 
    Deciphera Logo
      
Solid Tumors in Combination with Carboplatin
(includes mesothelioma, ovarian & breast cancers)
 
 

 

    
DCC-3116: Selective Inhibitor of ULK
Autophagy Inhibitor Targeting RAS Mutant Cancers
 
    Deciphera Logo
      
Additional Programs
Immunokinase
(undisclosed kinase)
 
 

 

    Deciphera Logo
Ripretinib*: Broad Spectrum Inhibitor of KIT & PDGFRα
Phase Commercial Rights
GIST ≥4th Line (INVICTUS Study)   Regulatory Submission Deciphera
Development and commercialization exclusive license with Zai Lab in Greater China.
GIST 2nd Line (INTRIGUE Study)   Phase 3 Deciphera
Systemic Mastocytosis and Other Solid Tumors   Phase 1 Deciphera
DCC-3014: Selective Inhibitor of CSF1R
Phase Commercial Rights
Tenosynovial Giant Cell Tumors   Phase 1 Deciphera
Other Solid Tumors   Phase 1 Deciphera
Rebastinib: Selective Inhibitor of TIE2
Phase Commercial Rights
Solid Tumors in Combination with Paclitaxel
(includes breast, ovarian & endometrial cancers)
 
Phase 1b/2 Deciphera
Solid Tumors in Combination with Carboplatin
(includes mesothelioma, ovarian & breast cancers)
 
Phase 1b/2 Deciphera
DCC-3116: Selective Inhibitor of ULK
Phase Commercial Rights
Autophagy Inhibitor Targeting RAS Mutant Cancers Pre-clinical Deciphera
Additional Programs
Phase Commercial Rights
Immunokinase
(undisclosed kinase)
 
Pre-clinical Deciphera

*Development and commercialization exclusive license with Zai Lab in Greater China.